Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JS201 + lenvatinib
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
JS201 + lenvatinib is an investigational combination therapy being studied for small-cell lung cancer (SCLC). JS201 is a dual antibody targeting both PD-1 and TGF-β signaling pathways. It aims to optimize the tumor microenvironment by inhibiting extracellular matrix formation and angiogenesis, while potentially increasing immune response. Lenvatinib (brand name LENVIMA) is an established multikinase inhibitor with immunomodulatory effects. It is approved for use in several cancer types, often combined with other therapies. This combination is currently being evaluated in a phase II clinical study for SCLC that has progressed after prior chemotherapy and PD-L1 inhibitors. The study assesses efficacy (primary endpoint: objective response rate) and safety.
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)TGFB (GARP–latent transforming growth factor beta 1 complex)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)CD274 (Programmed cell death protein 1 ligand 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on JS201 + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JS201 + lenvatinib.